Eagle Pharmaceuticals Appoints New CFO

Eagle Pharmaceuticals announced Pete A. Meyers has joined the Company as Chief Financial Officer. Meyers will also serve as the company’s principal financial officer and principal accounting officer.

Meyers has over two decades of experience in the health care industry. He most recently served as Chief Financial Officer of Motif BioSciences. Prior to his role at Motif, he served as Chief Financial Officer and Treasurer of TetraLogic Pharmaceuticals Corporation. Meyers also spent 18 years as a health care investment banker, most recently as Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Meyers currently serves on the Board of Directors of Prima BioMed, where he chairs the Audit Committee.

"Pete’s extensive operations experience in the biopharma sector will provide invaluable insight and guidance as we seek to expand our commercialization strategy to include our first product marketed exclusively by Eagle’s internal sales organization, Ryanodex (dantrolene sodium) for the treatment of exertional heat stroke, if approved," Scott Tarriff, Chief Executive Officer of Eagle Pharmaceuticals said. Pete’s expertise will complement the capabilities of our senior management team, and we look forward to working with him on this and other projects."